Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.
2.

Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends.

Reece AS, Hulse GK.

Clin Pediatr (Phila). 2019 Jul 9:9922819861281. doi: 10.1177/0009922819861281. [Epub ahead of print]

PMID:
31288542
3.

Gastroschisis and Autism-Dual Canaries in the Californian Coalmine.

Reece AS, Hulse GK.

JAMA Surg. 2019 Feb 6. doi: 10.1001/jamasurg.2018.4694. [Epub ahead of print] No abstract available.

PMID:
30725103
4.

A case-control genome wide association study of substance use disorder (SUD) identifies novel variants on chromosome 7p14.1 in patients from the United Arab Emirates (UAE).

Alblooshi H, Al Safar H, Fisher HF, Cordell HJ, El Kashef A, Al Ghaferi H, Shawky M, Reece S, Hulse GK, Tay GK.

Am J Med Genet B Neuropsychiatr Genet. 2019 Jan;180(1):68-79. doi: 10.1002/ajmg.b.32708. Epub 2018 Dec 16.

PMID:
30556296
5.

Association of CamK2A genetic variants with transition time from occasional to regular heroin use in a sample of heroin-dependent individuals.

Eirich A, Biermann T, Müller CP, Kornhuber J, Benyamin B, Hulse GK, Wildenauer DB, Schwab SG.

Psychiatr Genet. 2019 Feb;29(1):18-25. doi: 10.1097/YPG.0000000000000208.

PMID:
30260900
6.

Pathways from epigenomics and glycobiology towards novel biomarkers of addiction and its radical cure.

Reece AS, Wang W, Hulse GK.

Med Hypotheses. 2018 Jul;116:10-21. doi: 10.1016/j.mehy.2018.04.011. Epub 2018 Apr 12.

PMID:
29857889
7.
8.

Serum ionic dysequilibria in clinical opioid dependence: Cross-sectional and longitudinal studies.

Reece AS, Norman A, Hulse GK.

Hum Exp Toxicol. 2017 Aug;36(8):776-784. doi: 10.1177/0960327116666649. Epub 2017 Jan 1.

PMID:
28703074
9.

Acceleration of cardiovascular-biological age by amphetamine exposure is a power function of chronological age.

Reece AS, Norman A, Hulse GK.

Heart Asia. 2017 Jan 10;9(1):30-38. doi: 10.1136/heartasia-2016-010832. eCollection 2017.

11.

Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study.

Reece AS, Norman A, Hulse GK.

BMJ Open. 2016 Nov 7;6(11):e011891. doi: 10.1136/bmjopen-2016-011891.

12.

Medicinal cannabis in Australia: the missing links.

Reece AS, Hulse GK.

Med J Aust. 2016 Nov 7;205(9):425. No abstract available.

PMID:
27809740
13.

Dramatic acceleration of reproductive aging, contraction of biochemical fecundity and healthspan-lifespan implications of opioid-induced endocrinopathy-FSH/LH ratio and other interrelationships.

Reece AS, Thomas MR, Norman A, Hulse GK.

Reprod Toxicol. 2016 Dec;66:20-30. doi: 10.1016/j.reprotox.2016.09.006. Epub 2016 Sep 20.

PMID:
27663472
14.

Erratum to "Emergency department based intervention with adolescent substance users: 10year economic and health outcomes" [Drug Alcohol Depend. 165 (2016) 168-174].

Tait RJ, Teoh L, Kelty E, Geelhoed E, Mountain D, Hulse GK.

Drug Alcohol Depend. 2016 Oct 1;167:236. doi: 10.1016/j.drugalcdep.2016.08.005. Epub 2016 Aug 8. No abstract available.

PMID:
27515724
15.

Emergency department based intervention with adolescent substance users: 10year economic and health outcomes.

Tait RJ, Teoh L, Kelty E, Geelhoed E, Mountain D, Hulse GK.

Drug Alcohol Depend. 2016 Aug 1;165:168-74. doi: 10.1016/j.drugalcdep.2016.06.005. Epub 2016 Jun 11.

PMID:
27317044
16.

Chromothripsis and epigenomics complete causality criteria for cannabis- and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity.

Reece AS, Hulse GK.

Mutat Res. 2016 Jul;789:15-25. doi: 10.1016/j.mrfmmm.2016.05.002. Epub 2016 May 4. Review.

PMID:
27208973
17.

The pattern of substance use disorder in the United Arab Emirates in 2015: results of a National Rehabilitation Centre cohort study.

Alblooshi H, Hulse GK, El Kashef A, Al Hashmi H, Shawky M, Al Ghaferi H, Al Safar H, Tay GK.

Subst Abuse Treat Prev Policy. 2016 May 13;11(1):19. doi: 10.1186/s13011-016-0062-5.

18.

Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1.

Hancock DB, Levy JL, Gaddis NC, Glasheen C, Saccone NL, Page GP, Hulse GK, Wildenauer D, Kelty EA, Schwab SG, Degenhardt L, Martin NG, Montgomery GW, Attia J, Holliday EG, McEvoy M, Scott RJ, Bierut LJ, Nelson EC, Kral AH, Johnson EO.

Biol Psychiatry. 2015 Oct 1;78(7):474-84. doi: 10.1016/j.biopsych.2015.01.003. Epub 2015 Jan 29.

19.
20.

Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.

Goonoo N, Bhaw-Luximon A, Ujoodha R, Jhugroo A, Hulse GK, Jhurry D.

J Control Release. 2014 Jun 10;183:154-66. doi: 10.1016/j.jconrel.2014.03.046. Epub 2014 Apr 2. Review.

PMID:
24704710
21.

Duration of opiate exposure as a determinant of arterial stiffness and vascular age in male opiate dependence: a longitudinal study.

Reece AS, Hulse GK.

J Clin Pharm Ther. 2014 Apr;39(2):158-67. doi: 10.1111/jcpt.12121. Epub 2013 Dec 16.

PMID:
24329809
22.

Lifetime opiate exposure as an independent and interactive cardiovascular risk factor in males: a cross-sectional clinical study.

Reece AS, Hulse GK.

Vasc Health Risk Manag. 2013;9:551-61. doi: 10.2147/VHRM.S48030. Epub 2013 Oct 2.

23.
24.

Reduction in arterial stiffness and vascular age by naltrexone-induced interruption of opiate agonism: a cohort study.

Reece AS, Hulse GK.

BMJ Open. 2013 Mar 21;3(3). pii: e002610. doi: 10.1136/bmjopen-2013-002610.

25.

Impact of opioid pharmacotherapy on arterial stiffness and vascular ageing: cross-sectional and longitudinal studies.

Reece AS, Hulse GK.

Cardiovasc Toxicol. 2013 Sep;13(3):254-66. doi: 10.1007/s12012-013-9204-4.

PMID:
23456431
26.

Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood.

Farid WO, Lawrence AJ, Krstew EV, Tait RJ, Hulse GK, Dunlop SA.

PLoS One. 2012;7(12):e52812. doi: 10.1371/journal.pone.0052812. Epub 2012 Dec 26.

27.

Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent.

Al-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK.

Pharmgenomics Pers Med. 2012;5:99-111. doi: 10.2147/PGPM.S33351. Epub 2012 Sep 7.

28.

Benzodiazepine dependence and its treatment with low dose flumazenil.

Hood SD, Norman A, Hince DA, Melichar JK, Hulse GK.

Br J Clin Pharmacol. 2014 Feb;77(2):285-94. doi: 10.1111/bcp.12023. Review.

29.

Characterization of serotonin transporter gene (SLC6A4) polymorphisms and its association with drug dependence in a Jordanian Arab population.

Al-Eitan LN, Jaradat SA, Qin W, Wildenauer DM, Wildenauer DD, Hulse GK, Tay GK.

Toxicol Ind Health. 2014 Aug;30(7):598-610. doi: 10.1177/0748233712462446. Epub 2012 Oct 2.

PMID:
23033208
30.

Elevation of central arterial stiffness and vascular ageing in opiate withdrawal: cross-sectional and longitudinal studies.

Reece AS, Hulse GK.

Cardiovasc Toxicol. 2013 Mar;13(1):55-67. doi: 10.1007/s12012-012-9186-7.

PMID:
22991174
31.

Custom genotyping for substance addiction susceptibility genes in Jordanians of Arab descent.

Al-Eitan LN, Jaradat SA, Hulse GK, Tay GK.

BMC Res Notes. 2012 Sep 10;5:497. doi: 10.1186/1756-0500-5-497.

32.

Improving clinical outcomes for naltrexone as a management of problem alcohol use.

Hulse GK.

Br J Clin Pharmacol. 2013 Nov;76(5):632-41. doi: 10.1111/j.1365-2125.2012.04452.x. Review.

33.

Motivation to quit smoking among hospitalised individuals with and without mental health disorders.

Siru R, Hulse GK, Khan RJ, Tait RJ.

Aust N Z J Psychiatry. 2010 Jul;44(7):640-7. doi: 10.3109/00048671003627413.

PMID:
20560851
34.

Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.

Hulse GK, Ngo HT, Tait RJ.

Biol Psychiatry. 2010 Aug 1;68(3):296-302. doi: 10.1016/j.biopsych.2010.04.003. Epub 2010 May 26.

PMID:
20537615
35.

Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance.

Ngo HT, Tait RJ, Hulse GK.

J Psychopharmacol. 2011 Jun;25(6):774-82. doi: 10.1177/0269881110364266. Epub 2010 Apr 1.

PMID:
20360157
36.

Subcutaneous naltrexone implants reduce opioid use in opiate dependent patients.

Hulse GK.

Evid Based Ment Health. 2010 Feb;13(1):25. doi: 10.1136/ebmh.13.1.25. No abstract available.

PMID:
20164522
37.

Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

Hulse GK, Morris N, Arnold-Reed D, Tait RJ.

Arch Gen Psychiatry. 2009 Oct;66(10):1108-15. doi: 10.1001/archgenpsychiatry.2009.130.

PMID:
19805701
38.

Assessing motivation to quit smoking in people with mental illness: a review.

Siru R, Hulse GK, Tait RJ.

Addiction. 2009 May;104(5):719-33. doi: 10.1111/j.1360-0443.2009.02545.x. Review.

PMID:
19413788
39.

The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Farid WO, Dunlop SA, Tait RJ, Hulse GK.

Curr Neuropharmacol. 2008 Jun;6(2):125-50. doi: 10.2174/157015908784533842.

40.

Minor pathological changes are induced by naltrexone-poly(DL-lactide) implants in pregnant rats.

Farid WO, McCallum D, Tait RJ, Dunlop SA, Hulse GK.

J Biomed Mater Res A. 2009 Dec 15;91(4):964-74. doi: 10.1002/jbm.a.32283.

PMID:
19097147
41.

Hospital morbidity associated with the natural history of heroin use.

Tait RJ, Hulse GK.

J Opioid Manag. 2008 Sep-Oct;4(5):321-7.

PMID:
19070270
42.

Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.

Ngo HT, Tait RJ, Hulse GK.

Arch Gen Psychiatry. 2008 Apr;65(4):457-65. doi: 10.1001/archpsyc.65.4.457.

PMID:
18391134
43.

Smoking is associated with reduced cortical regional gray matter density in brain regions associated with incipient Alzheimer disease.

Almeida OP, Garrido GJ, Lautenschlager NT, Hulse GK, Jamrozik K, Flicker L.

Am J Geriatr Psychiatry. 2008 Jan;16(1):92-8. doi: 10.1097/JGP.0b013e318157cad2.

PMID:
18165464
44.

Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.

Tait RJ, Ngo HT, Hulse GK.

J Subst Abuse Treat. 2008 Sep;35(2):116-24. Epub 2007 Oct 10.

PMID:
17931824
45.

A comparison of mental health hospital admissions in a cohort of heroin users prior to and after rapid opiate detoxification and oral naltrexone maintenance.

Arnold-Reed DE, O'Neil P, Holman CD, Bulsara MK, Rodiguez C, Gawthorne G, Tait RJ, Hulse GK.

Am J Drug Alcohol Abuse. 2007;33(5):655-64.

PMID:
17891658
46.

Biodegradability of naltrexone-poly(DL) lactide implants in vivo assessed under ultrasound in humans.

Hulse GK, Low VH, Stalenberg V, Morris N, Thompson RI, Tait RJ, Phan CT, Ngo HT, Arnold-Reed DE.

Addict Biol. 2008 Sep;13(3-4):364-72. Epub 2007 Sep 11.

PMID:
17850414
47.

Sustained-release naltrexone: novel treatment for opioid dependence.

Comer SD, Sullivan MA, Hulse GK.

Expert Opin Investig Drugs. 2007 Aug;16(8):1285-94. Review.

PMID:
17685876
48.

Blood naltrexone levels over time following naltrexone implant.

Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):23-8. Epub 2007 Jun 19.

PMID:
17651881
49.

Opioid overdose deaths can occur in patients with naltrexone implants.

Hulse GK, Tait RJ.

Med J Aust. 2007 Jul 2;187(1):54; author reply 56-7. No abstract available.

PMID:
17605708
50.

Supplemental Content

Loading ...
Support Center